METTL1 and acute myeloid leukemia: By applying the cytosine-based TET enzyme inhibitor (bobcat339 hydrochloride), which targets the overall DNA demethylation levels, to treat AML cells, we found that the transcription level of METTL1 was significantly decreased in AML cell lines after 24 h and 48 h treatment of bobcat339 hydrochloride, together with the downregulation of METTL1 proteins (Fig. 3C, D), suggesting that the DNA demethylation in METTL1 gene’s promoter region that regulated by Tet family might play a major role in regulating METTL1 activation in AML cells.